Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.48 |
| ▸ | CNR2 | P34972 | 7/20 | 0.47 |
| ▸ | CNR1 | P21554 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13523934 | 0.98 | CNR2 (0.49) | ESR1ESR2CNR2CNR1MAPT | |
| SCHEMBL13523933 | 0.94 | ESR1 (0.55) | ESR1ESR2CNR2CNR1MAPT | |
| SCHEMBL9506262 | 0.90 | MAPT (0.57) | ESR1ESR2CNR2CNR1MAPT | |
| SCHEMBL9505321 | 0.89 | MAPT (0.55) | ESR1ESR2CNR2CNR1MAPT | |
| SCHEMBL9506249 | 0.89 | MAPT (0.55) | ESR1ESR2CNR2CNR1MAPT | |
| SCHEMBL9503281 | 0.89 | MAPT (0.55) | ESR1ESR2CNR2CNR1MAPT | |
| SCHEMBL9504010 | 0.89 | MAPT (0.55) | ESR1ESR2CNR2CNR1MAPT | |
| SCHEMBL13523938 | 0.86 | ESR1 (0.64) | ESR1ESR2CNR2CNR1MAPT | |
| SCHEMBL13523930 | 0.86 | ESR1 (0.52) | ESR1ESR2CNR2CNR1MAPT | |
| SCHEMBL8540208 | 0.84 | MAPT (0.58) | ESR1ESR2MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230200218-A1 | LIGHT-EMITTING DEVICE INCLUDING AMINE COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE AMINE COMPOUND | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20230200218-A1 | LIGHT-EMITTING DEVICE INCLUDING AMINE COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE AMINE COMPOUND | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-06-22 | — | — | US | disclosed |
| EP-2049599-B1 | BASIC BISAZO COMPOUNDS | ARCHROMA IP GMBH (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-8921564-B2 | Basic bisazo compounds | CLARIANT FINANCE (BVI) LTD. (VG) | 2014-12-30 | — | — | US | disclosed |
| US-8921564-B2 | Basic bisazo compounds | CLARIANT FINANCE (BVI) LTD. (VG) | 2014-12-30 | — | — | US | disclosed |
| US-20100000033-A1 | Basic Bisazo Compounds | CLARIANT FINANCE (BVI) LIMITED (VG) | 2010-01-07 | — | — | US | disclosed |
| US-20100000033-A1 | Basic Bisazo Compounds | CLARIANT FINANCE (BVI) LIMITED (VG) | 2010-01-07 | — | — | US | disclosed |
| WO-2008012322-A1 | BASIC BISAZO COMPOUNDS | CLARIANT INTERNATIONAL LTD (CH) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230200218-A1 | LIGHT-EMITTING DEVICE INCLUDING AMINE COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE AMINE COMPOUND | SLC18A1, CRY1, AADAT | ESR1 52/4885ESR2 328/4885CNR2 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.